Azithromycin for Critical Asthma - Pediatrics
Recruiting · NCT06223828 · Interventional (participants receive a specific treatment) · Lead sponsor: Johns Hopkins All Children's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Who can take part
Age range
3 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 3-17 years
- Admission to the PICU
- Primary diagnosis of critical asthma
- Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
- Prescription for intravenous systemic corticosteroids
Exclusion criteria
- Critical Congenital Heart Disease Unrepaired
- Tracheostomy Dependence at Admission
- Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
- Past Medical History of Prolonged QT Syndrome or Arrhythmias
- Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
Where it is running
1 location listed across 1 US state.
- Johns Hopkins All Children's Hospital - St. Petersburg, Florida, United States